Going-concern and financing risk
The company has recurring losses and limited cash, so it may need additional capital to fund operations and product development.
- Scope
- Corporate liquidity
- Materiality
- high
Aspira Women's Health Inc.
Aspira Women's Health Inc. develops and commercializes biomarker-based diagnostic tests for women’s health, with an initial focus on ovarian cancer risk assessment and broader gynecologic disease differentiation. The company operates Aspira Labs in Austin, Texas, where it performs its own testing workflow and delivers results to prescribing physicians. Its commercial model combines proprietary diagnostics, laboratory services, payer reimbursement, and partnerships intended to expand distribution and future product reach. Recent disclosures show the company is also trying to extend its platform into endometriosis, benign pelvic mass monitoring, and other high-unmet-need pelvic disease conditions.
−2 296,2 %
1 724,5 %
−3 725,9 %
−91,4 %
1.17
1.10
| % | |
|---|---|
| Diagnostic laboratory testing | 85% Biomarker-based tests performed by Aspira Labs and reported to physicians for clinical decision support. |
| Women’s health molecular diagnostics | 10% Proprietary tests focused on ovarian cancer and broader gynecologic disease differentiation. |
| Partnerships and out-licensing | 5% Commercial collaborations, specimen/research collaborations, distribution agreements, and potential out-licensing. |
Aspira sells primarily into the U.S. healthcare system, where its customers are physicians, healthcare systems, and...
- Physicians and specialist practicesprimary
Order OvaSuite, Ova1Plus, OvaWatch, and future tests to improve diagnostic confidence and referral decisions.
- Healthcare systemssecondary
Adopt decentralized or integrated testing workflows to standardize care pathways and support broader utilization.
- Payers and Medicare contractorsprimary
Provide coverage and reimbursement that directly affects test adoption and realized revenue.
- Patientssecondary
Ultimately receive the tests through physicians and influence demand through willingness to undergo diagnostic evaluation.
- Commercial and distribution partnersemerging
Support market expansion outside the core U.S. channel through collaborations, licensing, and distribution agreements.
Aspira’s operating base is in Austin, Texas, where Aspira Labs performs its diagnostic testing...
- •Austin, Texas is the core laboratory and operating location
- •U.S. healthcare payers are the main source of reimbursement
- •Novitas coverage for Texas testing supports Medicare access
- •State lab licenses in CA, MD, NY, PA, and RI expand compliance reach
- •International expansion is planned through partners, not a large direct footprint
- •Geographic concentration increases dependence on U.S. reimbursement policy
Aspira’s strategy is to move beyond ovarian cancer and position its biomarker platform as a broader diagnostic tool for...
01
Expand clinical use beyond ovarian cancermedium-term
A broader indication set can increase test volume and reduce dependence on a single disease category.
02
Secure reimbursement and payer coverageshort-term
Coverage determines whether physicians can adopt the tests at scale and whether revenue is collectible.
03
Grow physician and healthcare-system adoptionshort-term
Utilization growth is necessary to turn the laboratory platform into a recurring revenue base.
04
Build laboratory and molecular capabilitiesmedium-term
Internal lab capacity supports product execution, quality control, and future assay development.
Aspira remains a loss-making company with limited cash resources, so execution risk around financing,...
Reimbursement and coverage risk
Revenue realization depends on payer acceptance, Medicare coverage, and local coverage determinations for tests such as OvaWatch.
- Scope
- Ova1, OvaWatch, future tests
- Materiality
- high
Operational concentration risk
Testing is performed at Aspira Labs in Texas, so disruptions, compliance issues, or capacity constraints can directly affect revenue.
- Scope
- Aspira Labs
- Materiality
- high
Third-party dependency risk
The business relies on external providers such as Quest Diagnostics and BioReference Health for continuing services.
- Scope
- Laboratory and service operations
- Materiality
- medium
Low trading liquidity
OTC quotation and infrequent trading can make it difficult for investors to buy or sell shares at reasonable prices.
- Scope
- Capital markets
- Materiality
- medium
ASC 606 revenue recognition
Affects reported product revenue and gross margin
Collectability and payer mix estimates
Can materially change revenue recognized for the same test volume
Fair value of warrants and convertible notes
Affects earnings comparability period to period
Stock-based compensation and lease accounting
Influences operating loss and cash flow interpretation
VERACYTE, INC.
VCYT · Services-Medical Laboratories
Veracyte is a U.S.-based molecular diagnostics company that develops and commercializes genomic tests used in cancer and other disease areas.
Aspire Biopharma Holdings, Inc.
ASBP · Pharmaceutical Preparations
Anixa Biosciences Inc
ANIX · Pharmaceutical Preparations
Aura Biosciences, Inc.
AURA · Biological Products, (No Diagnostic Substances)
Aprea Therapeutics, Inc.
APRE · Pharmaceutical Preparations
Azitra, Inc.
AZTR · Pharmaceutical Preparations
: 11/08/2026